ASGCT 2024: Mammoth Sizes Up Genome Editing Opportunities
We catch up with Mammoth Biosciences CSO Lucas Harrington after his ASGCT presentation. Harrington lays out his company’s big plans in developing a range of therapeutic options using miniature Cas nucleases as well as the company’s recently disclosed alliance with Regeneron.